4DMedical Ltd (ASX: 4DX) shares closed 1.06% lower on Tuesday afternoon, at $3.72 a piece.
It's been a volatile start to 2026 for the ASX medical technology stock, with its share price fluctuating between a low of $3.10 in February and an all time high of $6.80 in April around the time it joined the S&P/ASX 200 Index (ASX: XJO).
The shares have now fallen over 45% since that April peak and are down around 18% for the year-to-date.
It looks like a broad sell off of healthcare stocks have driven the share price lower over the past couple of months. It's also likely that many investors rushed to take their gains off the table after an incredible run up over the past 12 months.
Image source: Getty Images
So, if I invested $5,000 in 4DMedical shares 12 months ago, how much would I have today?
Any investors who bought $5,000 of healthcare shares a year ago would be jumping for joy right now, even after the sell off over the past two months.
At the time of writing, 4DMedical shares are $3.72 a piece, which is an enormous 1,277.78% higher than just 12 months ago.
That means a $5,000 investment on the 16th of June last year would now be worth a whopping $68,889!
That is some epic gains.
What's next for the ASX healthcare stock?
4DMedical is an Australian medical technology company that provides breakthrough and non-invasive imaging software that maps lung function in real time.
It visually highlights 4D images of airflow and ventilation without the need for any radioactive contrast dyes or invasive procedures. The technology is used to help identify and treat lung and respiratory diseases ranging from asthma to lung cancer.
The company saw its share price explode in 2025 after its flagship product, CT:VQ, received regulatory approvals. It was quickly implemented and adopted through various contracts and partnerships with major hospitals and medical providers, primarily across the US.
The leap in development and fast adoption means 4DMedical moved very quickly from a research and development business to a globally commercial business.
The company is still in its growth phase and is working to build out its commercial footprint even further. Approvals have been secured in Canada and New Zealand. The company is now actively progressing commercialisation plans in Europe and Australia.
There is clearly a lot of potential for the business to keep growing.
But the question is, can its share price keep climbing at the same rate?
Here's what the experts think.
Are 4DMedical shares a buy, sell or hold?
According to TradingView data, analysts are very split. Of three analysts with recorded ratings, there is one strong buy, one hold, and one strong sell. That's quite a swing.
Target prices vary wildly too.
The maximum $6 target price implies a potential 61% upside at the time of writing. Meanwhile, the minimum $3 target price suggests the shares could fall another 19% from here.
